Aveanna Healthcare (NASDAQ:AVAH) Stock Price Expected to Rise, UBS Group Analyst Says

Aveanna Healthcare (NASDAQ:AVAH) had its price objective boosted by stock analysts at UBS Group from $8.00 to $13.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm presently has a “neutral” rating on the stock. UBS Group’s price objective would suggest a potential upside of 5.56% from the company’s current price.

Several other equities analysts also recently issued reports on AVAH. Weiss Ratings restated a “hold (c+)” rating on shares of Aveanna Healthcare in a research note on Thursday, July 2nd. Raymond James Financial lifted their target price on Aveanna Healthcare from $13.00 to $15.00 and gave the stock a “strong-buy” rating in a research report on Friday. Stephens raised Aveanna Healthcare from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $10.00 to $11.00 in a report on Friday, May 15th. Royal Bank Of Canada upgraded Aveanna Healthcare from a “sector perform” rating to an “outperform” rating and set a $10.00 price target on the stock in a research note on Wednesday, June 3rd. Finally, Barclays lifted their price target on Aveanna Healthcare from $9.00 to $9.50 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $11.78.

Aveanna Healthcare Stock Up 9.1%

Shares of NASDAQ AVAH traded up $1.02 during midday trading on Friday, hitting $12.31. 4,391,567 shares of the company’s stock were exchanged, compared to its average volume of 1,666,656. The company has a debt-to-equity ratio of 5.35, a current ratio of 1.47 and a quick ratio of 1.47. Aveanna Healthcare has a twelve month low of $5.93 and a twelve month high of $12.52. The firm’s fifty day simple moving average is $8.86 and its 200-day simple moving average is $7.73. The company has a market cap of $2.68 billion, a PE ratio of 10.43, a P/E/G ratio of 0.90 and a beta of 1.90.

Aveanna Healthcare (NASDAQ:AVAH) last issued its earnings results on Thursday, August 13th. The company reported $0.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.19 by $0.03. Aveanna Healthcare had a net margin of 10.37% and a return on equity of 124.68%. The business had revenue of $670.48 million during the quarter, compared to analysts’ expectations of $638.61 million. Research analysts predict that Aveanna Healthcare will post 0.68 EPS for the current fiscal year.

Insider Buying and Selling

In related news, major shareholder Paul R. Vigano sold 7,000,000 shares of Aveanna Healthcare stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $6.24, for a total value of $43,680,000.00. Following the transaction, the insider directly owned 252,899 shares in the company, valued at $1,578,089.76. This trade represents a 96.51% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Patrick A. Cunningham sold 125,000 shares of the business’s stock in a transaction on Wednesday, May 20th. The shares were sold at an average price of $7.59, for a total transaction of $948,750.00. Following the completion of the transaction, the insider directly owned 212,755 shares in the company, valued at $1,614,810.45. This represents a 37.01% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 31,305,664 shares of company stock worth $215,555,910. 5.30% of the stock is currently owned by company insiders.

Institutional Trading of Aveanna Healthcare

Several hedge funds and other institutional investors have recently made changes to their positions in AVAH. Caitong International Asset Management Co. Ltd increased its stake in shares of Aveanna Healthcare by 252.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,351 shares of the company’s stock worth $27,000 after acquiring an additional 2,400 shares during the period. Quantbot Technologies LP acquired a new stake in Aveanna Healthcare in the second quarter valued at about $43,000. Summit Securities Group LLC acquired a new stake in Aveanna Healthcare in the first quarter valued at about $53,000. Oxford Asset Management LLP purchased a new stake in Aveanna Healthcare in the 2nd quarter valued at approximately $64,000. Finally, C M Bidwell & Associates Ltd. acquired a new position in Aveanna Healthcare during the 2nd quarter worth approximately $69,000. Hedge funds and other institutional investors own 87.96% of the company’s stock.

Aveanna Healthcare News Roundup

Here are the key news stories impacting Aveanna Healthcare this week:

• Positive Sentiment: Strong Q2 beat: Aveanna reported revenue of $670.5 million, up 13.7% year over year, and adjusted earnings of $0.22 per share, exceeding analyst expectations. Net income rose to $40.3 million from $27.0 million, while adjusted EBITDA increased 8% to $95.4 million. Aveanna Healthcare second-quarter results and revised guidance
• Positive Sentiment: Guidance raised: Management now expects 2026 revenue above $2.68 billion, compared with its previous range of $2.63 billion to $2.65 billion. Full-year adjusted EBITDA guidance was increased to more than $365 million from $338 million to $342 million. AVAH Q2 earnings call highlights
• Positive Sentiment: Improved growth outlook: On its earnings call, Aveanna highlighted reimbursement gains, expanding relationships with preferred payers and higher long-term growth targets, supporting expectations for continued demand across its home-care platform.
• Positive Sentiment: Analyst endorsement: BMO Capital Markets raised its AVAH price target from $10 to $14 and upgraded or maintained an “outperform” rating, reinforcing the market’s favorable response to the earnings report.
• Neutral Sentiment: Valuation and momentum: The stock is trading near its 12-month high after gaining substantially since March. Although its forward valuation remains attractive relative to some healthcare peers, the recent rally may increase sensitivity to future results.
• Negative Sentiment: Margin pressure remains a risk: Gross margins declined across Aveanna’s business segments, including Private Duty Services, which generates most of the company’s revenue. Continued revenue growth is currently offsetting that pressure, but weaker margins could limit future earnings expansion.

Aveanna Healthcare Company Profile

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.